Related Experiment Videos
Advanced Merkel cell cancer and the elderly
1Department of Medical Oncology, Cork University Hospital, Wilton, Cork. brianbird@eircom.net
Irish Journal of Medical Science
|May 5, 2005
Summary
Merkel cell cancer (MCC), a rare skin cancer, shows good response to chemotherapy in elderly patients. Treatment with carboplatin and etoposide improved quality of life in a case of advanced MCC.
Area of Science:
- Oncology
- Dermatology
- Medical Oncology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
- Primarily affects elderly Caucasians, with a propensity for metastasis to lymph nodes and viscera.
- MCC exhibits sensitivity to chemotherapy but is characterized by rapid recurrence.
Observation:
- A case report of a 73-year-old male diagnosed with MCC.
- The patient presented with a fungating primary lesion on the knee and ulcerated inguinal lymph nodes.
- Treatment involved chemotherapy with carboplatin and etoposide.
Findings:
- The patient experienced ulcer healing and improved quality of life after two cycles of chemotherapy.
- Literature review indicates overall response rates approaching 60% with chemotherapy.
- Despite treatment, median survival remains limited at nine months for metastatic MCC.
Implications:
- Chemotherapy is a viable treatment option for elderly patients with advanced or recurrent MCC.
- Highlights the need for effective therapeutic strategies for this rare and aggressive skin cancer.
- Suggests careful consideration of chemotherapy for fit elderly individuals diagnosed with MCC.